Topics
-
Why the FDA’s Push for Real-Time Clinical Trials Favors Big Pharma
The FDA’s push for real-time clinical trial monitoring promises to accelerate drug approvals, but the immense technological requirements threaten to…
Read More » -
Paralysis by Analysis: Why Modern Health Advice is Leaving Us Stalled
A new Abbott survey reveals that 65% of U.S. adults have delayed or avoided health actions due to feeling overwhelmed…
Read More » -
Liminatus Pharma Advances Immuno-Oncology Pipeline with Phase 1 Trial of IBA101
Liminatus Pharma has announced a Phase 1 clinical trial for IBA101, a next-generation antibody designed to block the CD47 "don’t-eat-me"…
Read More » -
Is AI Slashing Pharma Jobs? Why the Laboratory Might Be Safer Than the Office
While AI is triggering massive layoffs across the tech sector, the biopharma industry is bucking the trend by leveraging the…
Read More » -
The Agentic Leap: How AI’s Shift to Active Participation Will Transform Pharma by 2026
2026 is poised to be the year AI's role in the pharmaceutical industry shifts dramatically from passive analysis to active,…
Read More » -
Eli Lilly and NVIDIA Forge Alliance to Build AI Drug Discovery Supercomputer
Eli Lilly and NVIDIA have partnered to build the most powerful AI-powered supercomputer in the pharmaceutical industry, creating an "AI…
Read More » -
How AI Will Shape the Future of Drug Discovery
An AI revolution is reshaping the future of drug discovery by accelerating the process and enabling a new era of…
Read More » -
AI in Biopharma: Navigating the “Massive Transition” in Drugmaking Leadership
The artificial intelligence (AI) revolution is causing a fascinating tension in biopharma, as groundbreaking technology clashes with traditional drugmaking methods.…
Read More » -
Pharma’s Struggle to Connect in the Age of Virtual Care
The pharmaceutical industry is struggling to keep pace with rapid changes in healthcare, particularly in how it connects with patients…
Read More » -
Pharmaceutical Industry Under Pressure: Where Will Clinical Trial Efficiencies Come From?
The Trump Administration's 'Most Favored Nation' drug pricing policy raises concerns for pharmaceutical companies regarding clinical development and NIH funding.…
Read More »